0001610717-24-000098.txt : 20240228 0001610717-24-000098.hdr.sgml : 20240228 20240228173212 ACCESSION NUMBER: 0001610717-24-000098 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLATT LAWRENCE CENTRAL INDEX KEY: 0001242110 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 24697335 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-02-27 0001799448 Aligos Therapeutics, Inc. ALGS 0001242110 BLATT LAWRENCE C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 true true Chief Executive Officer false Stock Option (Right to Buy) 16.18 2024-02-27 4 D 0 450000 0 D 2021-01-01 2030-12-01 Common Stock 450000 0 D Stock Option (Right to Buy) 3.06 2024-02-27 4 D 0 323400 0 D 2022-03-04 2032-02-04 Common Stock 323400 0 D Stock Option (Right to Buy) 3.06 2024-02-27 4 D 0 80850 0 D 2025-02-04 2032-02-04 Common Stock 80850 0 D Stock Option (Right to Buy) 0.96 2024-02-28 4 A 0 132352 0 A 2030-12-01 Common Stock 132352 132352 D Stock Option (Right to Buy) 0.96 2024-02-28 4 A 0 230999 0 A 2032-02-04 Common Stock 230999 230999 D Stock Option (Right to Buy) 0.96 2024-02-28 4 A 0 57749 0 A 2032-02-04 Common Stock 57749 57749 D On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. /s/ Lesley Ann Calhoun, as attorney-in fact for Lawrence M. Blatt 2024-02-28